Data as of Mar 13
| -0.10 / -4.29%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 5.00 and a low estimate of 2.50. The median estimate represents a +12.11% increase from the last price of 2.23.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.